You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed Cell Death Receptor 1 (PD-1)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Advanced Solid Tumors Trial in United States (ARRY-382, Pembrolizumab)

Terminated
Has Results
  • Advanced Solid Tumors
  • Los Angeles, California
  • +29 more
May 21, 2022

Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

Not yet recruiting
  • Acute Lymphoblastic Leukemia in Pediatric
  • flow cytometric immunophynotyping
  • Sohag, Egypt
    Sohag University Hospital
Jun 19, 2022

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil)

Recruiting
  • Hepatitis B, Chronic
  • Vancouver, British Columbia, Canada
  • +31 more
Jan 17, 2023

PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
  • Non-small Cell Lung Cancer
  • Monza, Italy
    ASST-Monza Ospedale San Gerardo
Jun 9, 2022

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Castration-Resistant Prostatic Tumors Trial in Worldwide (Cetrelimab 480 mg, Apalutamide 240 mg)

Completed
  • Castration-Resistant Prostatic Neoplasms
  • Cetrelimab 480 mg
  • Apalutamide 240 mg
  • San Francisco, California
  • +33 more
Feb 24, 2022

Cancer Trial in United States (JTX-8064, pimivalimab)

Recruiting
  • Cancer
  • Birmingham, Alabama
  • +41 more
Feb 25, 2022

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

Not yet recruiting
  • Nasopharyngeal and Hypopharyngeal Carcinoma
  • immunohistochemical
  • Sohag, Egypt
    Sohag University Hospital
Oct 23, 2022

Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

Recruiting
  • Breast Cancer
  • +2 more
  • Observational Study
  • Lucknow, Uttar Pradesh, India
    Sanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

Active, not recruiting
  • Metastatic Nonsmall Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Stereotactic Body Radiotherapy
  • Philadelphia, Pennsylvania
    Philadelphia CyberKnife
Mar 15, 2022

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023